| |
Day 7
|
Day 37
|
|---|
|
N
|
%
|
N
|
%
|
|---|
|
Total (N = 125)
|
Clinical Cure
|
89
|
71.2
|
107
|
85.6
|
|
Improvement
|
24
|
19.2
|
10
|
8.0
|
|
Clinical Failure
|
12
|
9.6
|
8
|
6.4
|
|
≤45 years (N = 68)
|
Clinical Cure
|
55
|
80.9
|
64
|
94.1
|
|
Improvement
|
9
|
13.2
|
2
|
2.9
|
|
Clinical Failure
|
4
|
5.9
|
2
|
2.9
|
|
>45 years (N = 57)
|
Clinical Cure
|
34
|
59.7
|
43
|
75.4
|
|
Improvement
|
15
|
26.3
|
8
|
14.0
|
|
Clinical Failure
|
8
|
14.0
|
6
|
10.5
|
- Number (N) and percentage (%) of patients whose symptom status was assessed as “clinical cure” (sum score* ≤ 3), “improvement” (3 < sum score < 6) or “clinical failure” (sum score ≥ 6) on Day 7 and Day 37, for all patients and categorized into women aged ≤ 45 years or > 45 years (full analysis set, N = 125)
- *sum of the three main symptoms (dysuria, frequency and urgency) rated on a 5-point scale (0 – absence, 1 – mild, 2 – moderate, 3 – severe, 4 – very severe)
